摘要
系统性红斑狼疮(SLE)的发生及发展受表观遗传学机制的调控,其中组蛋白的修饰作用尤为重要。SLE患者存在自身反应性T细胞和B细胞的组蛋白修饰模式的改变,包括甲基化(CREMα、CXCR5、HPK1、EZH2、TNFAIP3和BACH2等)、乙酰化(BCL-6、BACH2和IL-2/10/17等)、磷酸化和泛素化等,并且这些改变可能是由特异性组蛋白修饰酶的水平变化所引起,而组蛋白修饰酶及组蛋白修饰水平的变化在SLE中的作用目前尚处于探索阶段。本文就组蛋白修饰在SLE中的研究进展进行简述,同时介绍针对表观遗传学靶点的治疗药物。
The occurrence and development of systemic lupus erythematosus(SLE)are regulated by epigenetic mechanisms,and histone modifications also play an important role in disease progression.SLE patients exhibit changes in histone modification patterns of autoreactive T cells and B cells,including methylation(CREMα,CXCR5,HPK1,EZH2,TNFAIP3,BACH2,etc.),acetylation(BCL-6,BACH2,IL-2/10/17,etc.),phosphorylation,ubiquitination,etc.And these changes may be caused by changes in the level of specific histone modifying enzymes,while the role of histone modifying enzymes and changes in histone modifying levels in SLE is currently in the exploratory stage.This article provides a brief overview of the research progress of histone modification in SLE,and introduces therapeutic drugs targeting epigenetic targets.
作者
苗林
王清翠
陈晓华
MIAO Lin;WANG Qingcui;CHEN Xiaohua(Department of Clinical Laboratory,General Hospital of Central Theater Command,Hubei Province,Wuhan430070,China)
出处
《中国医药导报》
CAS
2023年第30期68-71,共4页
China Medical Herald
基金
“湖北省青年拔尖人才培养计划”经费项目(鄂组函[2021]10号)。
